Bullous dermatosis associated with gemcitabine therapy for non-small-cell lung carcinoma
| Autor: | El Mekki Fethi, Zendah Ines, Aissa Imen, El Farhati Sameh, Ghedira Habib, Khattab Amal |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Male
Pulmonary and Respiratory Medicine Antimetabolites Antineoplastic medicine.medical_specialty Pathology Lung Neoplasms Side effect medicine.medical_treatment Deoxycytidine Blister Carcinoma Non-Small-Cell Lung Lung carcinoma medicine Carcinoma Humans Lung cancer Aged Cisplatin Chemotherapy Lung business.industry Respiratory disease medicine.disease Gemcitabine Dermatology Bullous dermatosis medicine.anatomical_structure Drug Eruptions business medicine.drug |
| Zdroj: | Respiratory Medicine. 100:1463-1465 |
| ISSN: | 0954-6111 |
| DOI: | 10.1016/j.rmed.2005.11.027 |
| Popis: | SummaryGemcitabine considered is to be a well-tolerated cytostatic drug with little known side effects. Cutaneous reactions are well known but still rarely reported.We report the case of a 75-year-old man with stage IV non-small-cell lung carcinoma treated with combination of gemcitabine 1000mg/m2 and cisplatin 75mg/m2 repeated every 28 days, who developed bilateral cutaneous bullous lesions of lower limbs following gemcitabine administration. Histopathologic examination did not show any toxidermy aspect and there was not any sign of immunoglobulin deposit in direct immunofluorescence test. Chemotherapy was stopped and lesions disappeared without any treatment. Even delayed with regard to gemcitabine administration, the causal relationship of gemcitabine treatment with skin reaction is possible according to the Naranjo probability scale. Pathologists should be aware of this kind of side effect in managing chemotherapy drugs and report any dermatologic reactions in order to identify the cause of toxicity and avoid a misdiagnosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect